
Approximately three million people in Europe are affected by Inflammatory Bowel Disease (IBD). In addition to the debilitating symptoms, patients also face increased risks of complications, delayed growth in children and mental health challenges like depression. Crohn’s disease (CD), one of the most common forms of IBD, is chronic and incurable. Despite major advances in medication and therapeutic treatments, remission is still far from a universal experience and there is a persistent treatment gap. This is where the INTERCEPT project comes in. With the aim to verify and clinically validate a panel of biomarkers and build a blood risk score that can identify individuals with a high risk of developing CD, INTERCEPT is changing the conversation from treatment to prevention.




